Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CEP-11981 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | At least one 6-week (42-day) cycle in which patients will be treated daily with CEP-11981 for 28 days, followed by a treatment-free period of 14 days. |
| Name | Type | Description |
|---|---|---|
| CEP-11981 (kinase inhibitor) | DRUG | Patients will be treated with oral CEP-11981 once daily for 28 days, followed by a treatment-free period of 14 days. This 42-day (6-week) period will constitute 1 cycle. The starting dose for the study will be 3 mg/m2. Dose escalation from this starting dose follows a modified Fibonacci sequence. |
Key Inclusion Criteria: The patient: * has a histologically or cytologically confirmed solid tumor that has relapsed or is refractory. Additionally, the tumor must be considered unresponsive or poorly responsive to accepted treatment modalities. * has a life expectancy of at least 12 weeks. * has ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
CEP-11981 is an investigational small molecule being studied for the treatment of cancer. It is a kinase inhibitor that was evaluated in patients with advanced cancer. The drug is in Phase 1 clinical development and is not yet approved for any use.
CEP-11981 is a kinase inhibitor, meaning it works by blocking the activity of certain kinase enzymes that are involved in cancer cell growth and survival. By inhibiting these targets, the drug aims to slow or stop the progression of tumors in patients with advanced cancer.
CEP-11981 is being developed by Teva Pharmaceutical Industries Limited, a company publicly traded under the ticker symbol TEVA. The drug is currently in Phase 1 clinical development for the treatment of cancer.
CEP-11981 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied for safety and tolerability in patients with advanced cancer.
CEP-11981 has one completed clinical trial, registered under NCT00875264. This was an open-label, uncontrolled study designed to determine the maximum tolerated oral dose of CEP-11981 in patients with advanced cancer. The trial enrolled 43 participants.